## TRANSMITTAL SHEET FOR NOTICE OF INTENDED ACTION

Control	420	Alabama Departme	ent of Public Health
Rule Number 420-4-1, Appendix I Rule Title Alabama Notifiable Diseases/Conditions			
Ne	w XXXX Amend	RepealA	Adopt by Reference
	bsence of the proposed rule signification by the public health, welfare or safety?	•	Yes
	asonable relationship between the ne protection of the public health,		Yes
	her, less restrictive method of reg lequately protect the public?	ulation available	No
	oposed rule have the effect of dire ne costs of any goods or services i ree?		No
	se in cost, if any, more harmful to t might result from the absence of		<u>n/a</u>
	of the rulemaking process design nd so they have as their primary 6?		<u>Yes</u>
Does the pro	pposed rule have an economic imp	pact?	<u>No</u>
If the proposed rule has an economic impact, the proposed rule is required to be accompanied by a fiscal note prepared in accordance with subsection (f) of §41-22-23, <u>Code of Alabama</u> , 1975.			
Certification of Authorized Official			
I certify that the attached proposed rule has been in full compliance with the requirements of Chapter 22, Title 41, Code of Alabama, 1975, and that it conforms to all applicable filing requirements of the Administrative Procedure Division of the Legislative Reference Service.			
Signature of	Certifying Officer Jahui	en Blue D	Date 1/21/2014

## STATE BOARD OF HEALTH NOTICE OF INTENDED ACTION

AGENCY NAME: Alabama Department of Public Health

RULE NUMBER AND TITLE: 420-4-1, Alabama Notifiable Diseases/Conditions, Appendix I

INTENDED ACTION: Revision of Rule 420-4-1.

SUBSTANCE OF PROPOSED ACTION: To amend the current Notifiable Disease/Conditions Appendix to add drug overdose as a reportable condition.

TIME, PLACE, AND MANNER OF PRESENTING VIEWS: A public hearing will be held at 9:00 a.m. February 20, 2014, at the Alabama Department of Public Health, RSA Tower, Suite 1540, 201 Monroe Street, Montgomery, AL 36104.

FINAL DATE FOR COMMENTS AND COMPLETION OF NOTICE: Written or oral comments will be received until the close of the record at 5:00 p.m. on March 7, 2014. All comments and requests for copies of the proposed amendments should be addressed to the contact person listed below.

CONTACT PERSON AT AGENCY: Jamey Durham, Director of the Bureau of Professional & Support Services, Department of Public Health, 201 Monroe Street, Suite 1010, Montgomery, Alabama 36104. Telephone number (334) 206-5226..

Patricia E. Ivie, Agency Secretary

## APPENDIX I ALABAMA NOTIFIABLE DISEASES/CONDITIONS

Immediate, Extremely Urgent Disease/Condition - Report to the County or State Health Department by telephone or in person within 4 hours of diagnosis

Anthrax, human
Botulism
Plague
Poliomyelitis, paralytic
Severe Acute Respiratory Syndromeassociated Coronavirus (SARS-CoV) disease

Smallpox Tularemia

Viral hemorrhagic fever

Cases related to nuclear, biological, or

chemical terroristic agents

Immediate, Urgent Disease/Condition - Report to the County or State Health Department electronically, by telephone, facsimile, or in person within 24 hours of diagnosis

Brucellosis
Cholera
Diphtheria
Haemophilus influenzae,
invasive disease 
Hepatitis A
Measles (rubeola)

Meningococcal Disease (Neisseria meningitidis)<sup>1</sup> Novel influenza A virus infections

Pertussis
Poliovirus infection,
nonparalytic

Rabies, human and animal
Rubella
Tuberculosis
Typhoid fever
Yellow fever

Outbreaks of any kind Cases of potential public health importance <sup>2</sup>

Standard Notification Disease/Condition - Report electronically or in writing to the County or State Health Department within 7 days of diagnosis, unless otherwise noted

Asthma 3 Arboviral disease Babesiosis Campylobacteriosis Chancroid\* Chlamydia trachomatis\* Cryptosporidiosis Dengue Drug Overdose 4 E. coli, shiga toxinproducing (STEC), including O157:H7 Ehrlichiosis/Anaplasmosis Encephalitis, viral Giardiasis Gonorrhea\* Hansen's disease (Leprosy)

Giardiasis Malaria
Gonorrhea\* Mumps
Hansen's disease Psittacosis
(Leprosy) Q Fever
Hemolytic uremic syndrome Salmonellosis
(HUS), post-diarrheal Shigellosis

Hepatitis, B, C, and other viral Spotted Fever Histoplasmosis Rickettsiosis Human Immunodeficiency Virus Staphylococcus aureus, infection\* (including Vancomycin-intermediate asymptomatic infection, AIDS, (VISA) CD4 counts, and viral load) Staphylococcus aureus, Influenza-associated Vancomycin-resistant pediatric mortality (VRSA) Lead, exposure screening test Streptococcus pneumoniae, result invasive disease 1 Legionellosis Syphilis\* Leptospirosis Tetanus Listeriosis Toxic shock syndrome Lyme disease Trichinellosis (Trichinosis)

Varicella

Vibriosis

\*Designated Sexually Transmitted Diseases by the State Board of Health

detection of organism from a normally sterile body site (e.g., blood, cerebrospinal fluid, or, less commonly, joint, pleural or pericardial fluid)

<sup>&</sup>lt;sup>2</sup> as determined by the reporting healthcare provider

<sup>&</sup>lt;sup>3</sup> Asthma discharge data reporting is limited to hospitals and is to be reported quarterly to the Asthma Program for the duration of the Program's Cooperative Agreement with the CDC (5 years ending 8/31/2014). Data elements to be reported for all patients with a Primary, Secondary, or Tertiary ICD-9 Diagnosis Code of 493.XX (Asthma) are: Patient Age; Patient Date of Birth (DOB); Patient Gender; Patient Race and/or Ethnicity; City, County, State of Patient Residence; Admit Date and Discharge Date (or Length of Stay); Patient Payor Source; and Primary, Secondary, and Tertiary ICD-9 Diagnosis Codes. For the Reporting of Asthma, the data elements listed in Rule 420-4-1-.04 (5) may be replaced with those listed above.

<sup>4</sup> Drug overdose discharge data is limited to hospitals and is to be reported quarterly to the Prescription Drug Monitoring Program. Data elements to be reported are the number of overdoses encountered and the name of the drug(s) causing the overdose as set out in Schedules II through IV of the State Board of Health's Controlled Substances List, Chapter 420-7-2, Appendix.

State Health Department Telephone Numbers:

Bureau of Clinical Laboratories (334) 260-3400 (24-hour coverage)

Division of Chronic Disease Prevention (334) 206-3028

Division of Epidemiology (334) 206-5347 or 1-800-338-8374 (24-hour coverage), FAX: (334) 206-3734

Division of HIV/AIDS Prevention & Control (334) 206-5364 or 1-800-344-1153

Division of Immunization (334) 206-5023

Division of Sexually Transmitted Diseases (334) 206-5350

Division of Tuberculosis Control (334) 206-5330